Trial Profile
A study evaluating the effect of Natalizumab treatment on JCV-specific antibodies and on general as well as antiviral intrathecal B cell immunity systematically
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 27 Feb 2016 New trial record